Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis

Clinical Immunology

Volumn 142, Issue 2, 2012, Pages 127-138

  Lin, Jack T ^a   Stein, Emily A ^a,b   Wong, Michael T ^a   Kalpathy, Krishna J ^a   Su, Leon L ^a   Utz, Paul J ^a   Robinson, William H ^a,b   Fathman, C Garrison ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Activation pathways; CD4 T cells; CIA; Combination therapy; MAPK; MTOR

Indexed keywords

COLLAGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BENZAMIDES; BENZOPYRANS; CELL PROLIFERATION; CHROMONES; DIPHENYLAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MONOSACCHARIDES; MORPHOLINES; SIROLIMUS; T-LYMPHOCYTES, HELPER-INDUCER; TOR SERINE-THREONINE KINASES;

EID: 84856512814     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.09.008     Document Type: Article

References (31)

1. Pancer Z., Cooper M.D. The evolution of adaptive immunity. Annu. Rev. Immunol. 2006, 24:497-518.
2. St Clair E.W., Turka L.A., Saxon A., Matthews J.B., Sayegh M.H., Eisenbarth G.S., Bluestone J. New reagents on the horizon for immune tolerance. Annu. Rev. Med. 2007, 58:329-346.
3. Jager A., Kuchroo V.K. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand. J. Immunol. 2010, 72:173-184.
4. Lohr J., Knoechel B., Nagabhushanam V., Abbas A.K. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol. Rev. 2005, 204:116-127.
5. Podojil J.R., Miller S.D. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol. Rev. 2009, 229:337-355.
6. Riley J.L., June C.H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005, 105:13-21.
7. Watts T.H. Staying alive: T cell costimulation, CD28, and Bcl-xL. J. Immunol. 2010, 185:3785-3787.
8. Kallies A. Distinct regulation of effector and memory T-cell differentiation. Immunol. Cell Biol. 2008, 86:325-332.
9. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004, 22:745-763.
10. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Immunol. 2003, 4:835-842.
11. Colombetti S., Basso V., Mueller D.L., Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 2006, 176:2730-2738.
12. Dienz O., Eaton S.M., Krahl T.J., Diehl S., Charland C., Dodge J., Swain S.L., Budd R.C., Haynes L., Rincon M. Accumulation of NFAT mediates IL-2 expression in memory, but not naive, CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7175-7180.
13. Jenkins M.K., Khoruts A., Ingulli E., Mueller D.L., McSorley S.J., Reinhardt R.L., Itano A., Pape K.A. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 2001, 19:23-45.
14. Malek T.R. The biology of interleukin-2. Annu. Rev. Immunol. 2008, 26:453-479.
15. Schulz K.R., Danna E.A., Krutzik P.O., Nolan G.P. Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol. 2007, 8. 8.17.
16. Coligan J.E. Current Protocols in Immunology 1991, John Wiley and Sons, New York.
17. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315-324.
18. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33:301-311.
19. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., Powell J.D. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 2007, 178:2163-2170.
20. Thomson A.W., Turnquist H.R., Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 2009, 9:324-337.
21. Lin J.T., Lineberry N.B., Kattah M.G., Su L.L., Utz P.J., Fathman C.G., Wu L. Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J. Immunol. 2009, 182:5919-5928.
22. Proud C.G. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem. J. 2007, 403:217-234.
23. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
24. Anjum R., Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 2008, 9:747-758.
25. Salmond R.J., Emery J., Okkenhaug K., Zamoyska R. MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J. Immunol. 2009, 183:7388-7397.
26. Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B., Taunton J., Hershey J.W., Blenis J., Pende M., Sonenberg N. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006, 25:2781-2791.
27. Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J., Sonenberg N., Blenis J. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J. Biol. Chem. 2007, 282:14056-14064.
28. Soares A., Govender L., Hughes J., Mavakla W., de Kock M., Barnard C., Pienaar B., Janse van Rensburg E., Jacobs G., Khomba G., Stone L., Abel B., Scriba T.J., Hanekom W.A. Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J. Immunol. Methods 2010, 362:43-50.
29. Esposito M., Ruffini F., Bellone M., Gagliani N., Battaglia M., Martino G., Furlan R. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 2010, 220:52-63.
30. Donia M., Mangano K., Amoroso A., Mazzarino M., Imbesi R., Castrogiovanni P., Coco M., Meroni P., Nicoletti F. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J. Autoimmunol. 2009, 33:135-140.
31. Baeder W.L., Sredy J., Sehgal S.N., Chang J.Y., Adams L.M. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin. Exp. Immunol. 1992, 89:174-178.